Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Base de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
2.
Cell ; 184(15): 4048-4063.e32, 2021 07 22.
Artículo en Inglés | MEDLINE | ID: mdl-34233165

RESUMEN

Microglia, the resident immune cells of the brain, have emerged as crucial regulators of synaptic refinement and brain wiring. However, whether the remodeling of distinct synapse types during development is mediated by specialized microglia is unknown. Here, we show that GABA-receptive microglia selectively interact with inhibitory cortical synapses during a critical window of mouse postnatal development. GABA initiates a transcriptional synapse remodeling program within these specialized microglia, which in turn sculpt inhibitory connectivity without impacting excitatory synapses. Ablation of GABAB receptors within microglia impairs this process and leads to behavioral abnormalities. These findings demonstrate that brain wiring relies on the selective communication between matched neuronal and glial cell types.


Asunto(s)
Microglía/metabolismo , Inhibición Neural/fisiología , Ácido gamma-Aminobutírico/metabolismo , Animales , Animales Recién Nacidos , Conducta Animal , Regulación de la Expresión Génica , Células HEK293 , Humanos , Ratones , Parvalbúminas/metabolismo , Fenotipo , Receptores de GABA-B/metabolismo , Sinapsis/fisiología , Transcripción Genética
3.
Schizophr Res ; 180: 64-69, 2017 02.
Artículo en Inglés | MEDLINE | ID: mdl-27645107

RESUMEN

A goal of current schizophrenia (SZ) research is to understand how multiple risk genes work together with environmental factors to produce the disease. In schizophrenia, there is elevated delta frequency EEG power in the awake state, an elevation that can be mimicked in rodents by N-methyl-d-aspartate receptor (NMDAR) antagonist action in the thalamus. This thalamic delta can be blocked by dopamine D2 receptor antagonists, agents known to be therapeutic in SZ. Experiments suggest that these oscillations can interfere with brain function and may thus be causal in producing psychosis. Here we evaluate the question of whether well-established schizophrenia risk genes may interact to affect the delta generation process. We identify 19 risk genes that can plausibly work in a synergistic fashion to generate delta oscillations.


Asunto(s)
Predisposición Genética a la Enfermedad , Esquizofrenia/genética , Esquizofrenia/metabolismo , Tálamo/metabolismo , Animales , Ritmo Delta/fisiología , Humanos
4.
J Neurosci ; 36(44): 11151-11157, 2016 11 02.
Artículo en Inglés | MEDLINE | ID: mdl-27807157

RESUMEN

The NMDA receptor (NMDAR) hypofunction hypothesis of schizophrenia is supported by multiple lines of evidence. Notably, administration of the NMDAR antagonist, ketamine, to healthy human subjects has psychotogenic action, producing both positive and negative symptoms associated with schizophrenia. NMDARs have multiple subtypes, but the subtypes through which ketamine produces its psychotogenic effects are not known. Here we address this question using quantitative data that characterize ketamine's ability to block different NMDAR subtypes. Our calculations indicate that, at a concentration that has psychotogenic action in humans, ketamine blocks a substantial fraction of GluN2C subunit-containing receptors but has less effect on GluN2A-, GluN2B-, and GluN2D-containing receptors. Thus, GluN2C-containing receptors may have preferential involvement in psychotic states produced by ketamine. A separate line of experiments also points to a special role for GluN2C. That work demonstrates the ability of NMDAR antagonists to mimic the elevation in the awake-state δ frequency EEG power that occurs in schizophrenia. Physiological experiments in rodents show that NMDAR antagonists generate δ oscillations by their action on the GluN2C-containing NMDARs that are prevalent in the thalamus. Optogenetic experiments suggest that such oscillations could contribute to symptoms of schizophrenia.


Asunto(s)
Encéfalo/metabolismo , Ketamina , Psicosis Inducidas por Sustancias/metabolismo , Receptores de N-Metil-D-Aspartato/metabolismo , Esquizofrenia/metabolismo , Animales , Encéfalo/efectos de los fármacos , Medicina Basada en la Evidencia , Alucinógenos , Humanos , Psicosis Inducidas por Sustancias/etiología , Receptores de N-Metil-D-Aspartato/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA